de José AP, Carbayo J, Pocurull A, et al. - Researchers assessed how antiviral treatment in patients diagnosed with HCV (hepatitis C virus)-associated mixed cryoglobulinaemia (HCV-MC) can influence kidney prognosis and evolution in these patients. A total of 139 patients with HCV-MC recruited from 14 Spanish centres were analyzed in an observational multicentre cohort study, named the RENALCRYOGLOBULINEMIC study. Three groups of patients were formed on the basis of treatment received: treatment with direct-acting antiviral agents (DAAs) (n = 100) treatment with interferon and ribavirin (n = 24) and no treatment (n = 15). A median follow-up of 138 months revealed improved kidney survival and decreased mortality in patients who received DAA treatment for HCV-MC.